Skip to Content


In the US, Pembrolizumab (pembrolizumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Cervical Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Primary Mediastinal Large B-cell Lymphoma, Solid Tumors and Urothelial Carcinoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Antineoplastic agent: Monoclonal antibody

Chemical Name

Immunoglobulin G4-kappa, anti-[Homo sapiensPDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;Gamma4 heavy chain (1-447) [humanized VH (Homo sapiensIGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-120) -Homo sa (WHO)

Foreign Names

  • Pembrolizumabum (Latin)
  • Pembrolizumab (German)
  • Pembrolizumab (French)
  • Pembrolizumab (Spanish)

Generic Names

Brand Names

  • Keytruda
    Merck, Canada; Merck, Slovenia; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Slovakia; Merck Sharp & Dohme, United States; MSD, Switzerland; MSD France, France
    MSD SHARP & DOHME, Germany


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.